Literature DB >> 22875098

Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.

Jonathan M Payne1, Belinda Barton, E Arthur Shores, Kathryn N North.   

Abstract

Studies investigating behavior in mice with a heterozygous null mutation of the NF1 gene (Nf1 (+/-)) have provided critical insights into the molecular and cellular mechanisms underlying cognitive impairments associated with neurofibromatosis type 1 (NF1). Hyperactivation of the Ras-MAPK signaling cascade, which results in increased GABA-mediated inhibition and significantly reduced long-term potentiation, has been proposed as a core mechanism underlying Nf1 (+/-) mice deficits in visuospatial learning and attention. This assertion has been reinforced by preclinical trials that reveal that these impairments can be rescued both at a cognitive and cellular level. We attempted to demonstrate a phenotypic parallel between Nf1 (+/-) mice and children with NF1 using a well-validated measure of visuospatial learning. Children with NF1 (n = 71) and healthy controls (n = 29) were assessed on a computerized paired associate learning task. Interrelationships between visuospatial learning and other cognitive abilities that may influence performance, such as intelligence, attention and visuospatial function, were explored. Children with NF1 displayed significant impairments in visuospatial learning, with reduced initial retention and poorer learning across repeated trials. Importantly, we demonstrated that visuospatial learning was inferior in NF1 even after accounting for group differences in intelligence, sustained attention and visuospatial abilities. We have thus identified impaired visuospatial learning as a core phenotypic feature in children with NF1. These findings imply that hippocampal-based learning networks are dysfunctional in children with NF1 and provide validation for a primary outcome measure for clinical trials aiming to correct aberrant Ras signaling.

Entities:  

Mesh:

Year:  2012        PMID: 22875098     DOI: 10.1007/s00415-012-6620-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

Review 1.  Expression mechanisms underlying NMDA receptor-dependent long-term potentiation.

Authors:  R A Nicoll; R C Malenka
Journal:  Ann N Y Acad Sci       Date:  1999-04-30       Impact factor: 5.691

Review 2.  Cognitive profile of neurofibromatosis type 1.

Authors:  Terry M Levine; April Materek; Jessica Abel; Madeline O'Donnell; Laurie E Cutting
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

3.  The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.

Authors:  Shelley L Hyman; Arthur Shores; Kathryn N North
Journal:  Neurology       Date:  2005-10-11       Impact factor: 9.910

4.  Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1.

Authors:  Natalie Pride; Jonathan M Payne; Richard Webster; E Arthur Shores; Caroline Rae; Kathryn N North
Journal:  J Child Neurol       Date:  2010-02-08       Impact factor: 1.987

Review 5.  Brain structure and function in neurofibromatosis type 1: current concepts and future directions.

Authors:  Jonathan M Payne; Mahendranath D Moharir; Richard Webster; Kathryn N North
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-03       Impact factor: 10.154

Review 6.  Plasticity in the human central nervous system.

Authors:  S F Cooke; T V P Bliss
Journal:  Brain       Date:  2006-05-03       Impact factor: 13.501

Review 7.  Advances in the early detection of Alzheimer's disease.

Authors:  Peter J Nestor; Philip Scheltens; John R Hodges
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

8.  Cognitive control in adolescents with neurofibromatosis type 1.

Authors:  I Rowbotham; I M Pit-ten Cate; E J S Sonuga-Barke; S C J Huijbregts
Journal:  Neuropsychology       Date:  2009-01       Impact factor: 3.295

9.  Neuropsychological profile of children with neurofibromatosis, brain tumor, or both.

Authors:  B D Moore; J L Ater; M N Needle; J Slopis; D R Copeland
Journal:  J Child Neurol       Date:  1994-10       Impact factor: 1.987

10.  A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease.

Authors:  B J Sahakian; R G Morris; J L Evenden; A Heald; R Levy; M Philpot; T W Robbins
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

View more
  8 in total

1.  Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.

Authors:  Thijs van der Vaart; André B Rietman; Ellen Plasschaert; Eric Legius; Ype Elgersma; Henriëtte A Moll
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

Review 2.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

Review 3.  Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1.

Authors:  Martha Milade Torres Nupan; Alberto Velez Van Meerbeke; Claudia Alejandra López Cabra; Paula Marcela Herrera Gomez
Journal:  Front Pediatr       Date:  2017-10-30       Impact factor: 3.418

4.  Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1.

Authors:  Nicole J Ullrich; Jonathan M Payne; Karin S Walsh; Gary Cutter; Roger Packer; Kathryn North; Celiane Rey-Casserly
Journal:  Ann Clin Transl Neurol       Date:  2020-02-05       Impact factor: 4.511

5.  Steady-state visual evoked potentials in children with neurofibromatosis type 1: associations with behavioral rating scales and impact of psychostimulant medication.

Authors:  Eve Lalancette; Audrey-Rose Charlebois-Poirier; Kristian Agbogba; Inga Sophia Knoth; Emily J H Jones; Luke Mason; Sébastien Perreault; Sarah Lippé
Journal:  J Neurodev Disord       Date:  2022-07-22       Impact factor: 4.074

6.  Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.

Authors:  Jonathan M Payne; Belinda Barton; Nicole J Ullrich; Alan Cantor; Stephen J C Hearps; Gary Cutter; Tena Rosser; Karin S Walsh; Gerard A Gioia; Pamela L Wolters; James Tonsgard; Elizabeth Schorry; David Viskochil; Laura Klesse; Michael Fisher; David H Gutmann; Alcino J Silva; Scott J Hunter; Celiane Rey-Casserly; Nancy L Cantor; Anna W Byars; Peter L Stavinoha; Joseph D Ackerson; Carol L Armstrong; Jill Isenberg; Sharon H O'Neil; Roger J Packer; Bruce Korf; Maria T Acosta; Kathryn N North
Journal:  Neurology       Date:  2016-11-09       Impact factor: 9.910

7.  Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.

Authors:  Natalie A Pride; Belinda Barton; Paul Hutchins; David R Coghill; Mayuresh S Korgaonkar; Stephen J C Hearps; Melissa Rouel; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  BMJ Open       Date:  2018-08-30       Impact factor: 2.692

8.  Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.

Authors:  Jonathan M Payne; Stephen J C Hearps; Karin S Walsh; Iris Paltin; Belinda Barton; Nicole J Ullrich; Kristina M Haebich; David Coghill; Gerard A Gioia; Alan Cantor; Gary Cutter; James H Tonsgard; David Viskochil; Celiane Rey-Casserly; Elizabeth K Schorry; Joseph D Ackerson; Laura Klesse; Michael J Fisher; David H Gutmann; Tena Rosser; Roger J Packer; Bruce Korf; Maria T Acosta; Kathryn N North
Journal:  Ann Clin Transl Neurol       Date:  2019-12-03       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.